Equity Details
Price & Market Data
Price: $86.15
Daily Change: -$0.97 / 1.13%
Daily Range: $85.49 - $88.54
Market Cap: $4,709,495,808
Daily Volume: 347,122
Performance Metrics
1 Week: -4.53%
1 Month: -4.28%
3 Months: 69.52%
6 Months: 137.5%
1 Year: 329.0%
YTD: 109.1%
About Dianthus Therapeutics, Inc. (DNTH)
Financial insights into Dianthus Therapeutics, Inc. (DNTH). Current price: 86.15, daily change: -$0.97 / 1.13%. Market cap: 4,709,495,808. Performance metrics across all timeframes are updated.
Company Details
Employees: 92
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.